Antagonists of mineralocorticoid receptors in myocardial infarction: focus on eplerenone


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Acute myocardial infarction is one of the important health problems throughout the world, the starting point for the development of heart failure, increasing the risk of death of a patient at an earlier date. Aldosterone is one of the most important neurohormonal mediators of the renin-angiotensin-aldosterone system in the regulation of water and potassium balance. Highly selective aldosterone antagonist eplerenone, even added to standard therapy, significantly reduces the risk of serious cardiovascular complications, including sudden cardiac death and overall mortality. Among the undoubted advantages of eplerenone before non-selective aldosterone antagonists of the previous generation there are better tolerability, low incidence of adverse events and a large evidence base.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Aleksandr Khokhlov

Yaroslavl state medical university

Email: al46O935@yandex.ru
MD, professor, Head of Department of clinical pharmacology, Head of Center for clinical and pharmacological studies; Deputy Chairman of the Council of ethics of Ministry of Health, Chief freelance clinical pharmacologist of Central Federal district

Yuliya Rybachkova

Yaroslavl state medical university

Email: julia3111@mail.ru
PhD, Department of clinical pharmacology

Әдебиет тізімі

  1. Бокерия Л.А., Гудкова Р.Г. Сердечно-сосудистая хирургия. М.: Изд-во НЦССХ им. А.Н. Бакулева РАМН, 2010. [Bokeriya L.A., Gudkova R.G. Cardiovascular surgery. M.: publishing house of A.N. Bakulev Scientific center of cardiovascular surgery. RAMS, 2010 (in Russain)]
  2. Бубнова М.Г. Улучшение выживаемости больных после инфаркта миокарда с дисфункцией левого желудочка и признаками сердечной недостаточности: фокус на антагонисты альдостерона. CardioСоматика. 2012;1:3-10. [Bubnova M.G. Improving of survival of patients after myocardial infarction with left ventricular dysfunction and signs of heart failure: focus on aldosterone antagonists. CardioSomatika. 2012;1:3-10 (in Russain)]
  3. Карпов Ю.А., Сорокин Е.В. Антагонисты минералокортикоидных рецепторов при хронической сердечной недостаточности: показания к назначению и выбор препарата в свете современных знаний. АтмосферA. Новости кардиологии. 2015;1:21-6. [Karpov Yu.A., Sorokin Ye.V. Antagonists of the mineralocorticoid receptor in chronic heart failure: indications and drug selection in the light of modern knowledge. Atmosphere. News of cardiology. 2015;1:21-6 (in Russain)]
  4. Курочкина О.Н., Хохлов А.Л., Копылова Д.А., Богомолов А.Н. Медикаментозная терапия больных, перенесших инфаркт миокарда: врачебные назначения и приверженность пациентов. Вестник Волгоградского государственного медицинского университета. 2012;4(44):90-3. [Kurochkina O.N., Khokhlov A.L., Kopylova D.A., Bogomolov A.N. Drug therapy of patients after myocardial infarction: medical appointments and commitment to patients. Vestnik of Volgograd state medical university. 2012;4(44):90-3 (in Russain)]
  5. Лисенкова Л.А., Хохлов А.Л. Опыт работы клинического фармаколога в Ярославле. Проблемы стандартизации в здравоохранении. 2004;11:18-21. [Lisenkova L.A., Khokhlov A.L. The experience of clinical pharmacologist in Yaroslavl. Problems of standardization in health care. 2004;11:18-21 (in Russain)]
  6. Моисеев B.C. Сердечная недостаточность и достижения генетики. Сердечная недостаточность. 2000;4:121-30. [Moiseev V.S. Heart failure and genetics. Heart failure. 2000;4:121-30 (in Russain)]
  7. Хохлов А.Л., Лилеева Е.Г., Рыбачкова Ю.В., Сироткина А.М., Воронина Е.А. Значение определения полиморфизмов генов, отвечающих за активность ангиотензинпревращающего фермента у больных с артериальной гипертензией и хронической сердечной недостаточностью. Проблемы стандартизации в здравоохранении. 2012;3-4:41-4. [Khokhlov A.L., Lileev Ye.G., Rybachkova Yu.V., Sirotkina A.M., Voronina Ye.A. The significance of detection of polymorphisms in the genes responsible for the activity of angiotensin converting enzyme in patients with arterial hypertension and chronic heart failure. Problems of standardization in health care. 2012;3-4:41-4 (in Russain)]
  8. Aroor A.R., Demarco V.G., Jia G., Sun Z., Nistala R., Meininger G.A., Sowers J.R. The role of tissue renin-angiotensinaldosterone system in the development of endothelial dysfunction and arterial stiffness. Front. Endocrinol. 2013;4:161.
  9. Beygui F., Vicaut E., Ecollan P., Machecourt J., Van Belle E., Zannad F., Montalescot G. Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial. Am. Heart J. 2010;160:642-8.
  10. D'Alessandro R., Masarone D., Buono A., Gravino R., Rea A., Salerno G., Golia E., Ammendola E., Del Giorno G., Santangelo L., Russo M.G., Calabro R., Bossone E., Pacileo G., Limongelli G. Natriuretic peptides: molecular biology, pathophysiology and clinical implications for the cardiologist. Future Cardiol. 2013;4:519-34.
  11. de Gevigney G., Ecochard R., Rabilloud M. et al. Worsening of heart failure during hospital course in myocardial infarction is a factor of poor prognosis. Apropos of a prospective cohort study of 2,507 patients hospitalized with myocardial infarction: PRIMA study. Ann. Cardiol. Angeiol. (Paris). 2002;51:25-32.
  12. Dhillon S. Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms. Drugs. 2013;73(13):1451-62.
  13. Dzau V.J., Antman E.M., Black H.R., Hayes D.L., Manson J.E., Plutzky J., Popma J.J., Stevenson W. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006;114:2850-70.
  14. Eschalier R., McMurray J.J., Swedberg K., van Veldhuisen D.J., Krum H., Pocock S.J., Shi H., Vincent J., Rossignol P., Zannad F., Pitt B. Safety and efficacy of eplerenone in patients at high-risk for hyperkalemia and/or worsening renal function: analyses of EMPHASIS-HF study subgroups. J. Am. Coll. Cardiol. 2013;62(17):1 585-93.
  15. Hayashi M., Tsutamoto T., Wada A., Tsutsui T., Ishii C., Ohno K., Fujii M., Taniguchi A., Hamatani T., Nozato Y., Kataoka K., Morigami N., Ohnishi M., Kinoshita M., Horie M. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation. 2003;107:2559-65.
  16. Hellermann J.P., Jacobsen S.J., Reeder G., Lopez-Jimenez F., Weston S.A., Roger V.L. Heart failure after myocardial infarction: prevalence of preserved left ventricular systolic function in the community. Am. Heart J. 2003;145:7428.
  17. Iqbal J., Parviz Y., Pitt B., Newell-Price J., Al-Mohammad A., Zannad F. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure. Eur. J. Heart Fail. 2014;16(2):143-50.
  18. McMachon E. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr. Opin. Pharmacol. 2001;1:190-6.
  19. McMurray J.J., Adamopoulos S., Anker S.D., Auricchio A., Böhm M., Dickstein K., Falk V., Filippatos G., Fonseca C., Gomez-Sanchez M.A., Jaarsma T., Kober L., Lip G.Y., Maggioni A.P., Parkhomenko A., Pieske B.M., Popescu B.A., Ronnevik P.K., Rutten F.H., Schwitter J., Seferovic P., Stepinska J., Trindade P.T., Voors A.A., Zannad F., Zeiher A. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2012;33:1787-847.
  20. Mulatero P., Milan A., Williams T.A., Veglio F. Mineralocorticoid receptor blockade in the protection of target organ damage. Cardiovasc. Hematol. Agents. Med. Chem. 2006;4(1):75-91.
  21. Nagarajan V., Chamsi-Pasha M., Tang W.H. The role of aldosterone receptor antagonists in the management of heart failure: an update. Cleve Clin. J. Med. 2012;79(9):631-9.
  22. Nichols M., Townsend N., Scarborough P., Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur. Heart J. 2014;35(42):2950-9.
  23. O'Gara P., Kushner F., Ascheim D. et al. ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology Foundation/American Heart Association. Task force on practice guidelines. Circulation. 2013;127:e362-e425.
  24. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New Engl. J. Med. 2003;348:1309-21.
  25. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. New Engl. J. Med. 1999;341:709-17.
  26. Pratt-Ubunama M.N., Nishizaka M.K., Boedefeld R.L., Cofield S.S., Harding S.M., Calhoun D.A. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest. 2007;131(2):453-9.
  27. Rossi G.P., Bernini G., Caliumi C., Desideri G., Fabris B., Ferri C., Ganzaroli C., Giacchetti G., Letizia C., Maccario M., Mallamaci F., Mannelli M., Mattarello M.J., Moretti A., Palumbo G., Parenti G., Porteri E., Semplicini A., Rizzoni D., Rossi E., Boscaro M., Pessina A.C., Mantero F. A prospective study of the prevalence of primary aldosteronism in 1.125 hypertensive patients. J. Am. Coll. Cardiol. 2006;48:2293-300.
  28. Spencer F.A., Meyer T.E., Gore J.M., Goldberg R.J. Heterogeneity in the management and outcomes of patients with acute myocardial infarction complicated by heart failure. The National registry of myocardial infarction. Circulation. 2002;105:260-510.
  29. Steg P.G., Dabbous O.H., Feldman I I., Cohen-Solal A., Aumont M.C., Lopez-Sendon J., Budaj A., Goldberg R.J., Klein W., Anderson F.A. Jr. for the Global Registry of Acute Coronary Events (GRACE) investigators. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation. 2004;109:494-9.
  30. Struthers A., Krum H., Williams G.H. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin. Cardiol. 2008;31 (4):153-8.
  31. Szucs T.D., Holm M.V., Schwenkglenks M. et al. Costeffectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction - an analysis of the EPHESUS study from a Swiss perspective. Cardiovasc. Drugs Ther. 2006;20(3):193-204.
  32. Sudano I., Naegele M., Roas S., Périat D., Frank M., Kouroedov A., Noll G., Lüscher T.F., Enseleit F., Ruschitzka F., Flammer A.J. Vascular effects of eplerenone in coronary artery disease with preserved ejection fraction: a double-blind randomized placebo-controlled trial. Clin. Cardiol. 2016;39(5):285-90.
  33. Thanh N.X., Ezekowitz J.A., Tran D.T., Kaul P. Cost effectiveness of eplerenone for the treatment of systolic heart failure with mild symptoms in Alberta, Canada. Am. J. Cardiovasc Drugs. 2016 Jun 14. [Epub ahead of print]
  34. The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet. 2001 ;357:1385-90.
  35. van den Berg T.N., Rongen G.A., Fröhlich G.M., Deinum J., Hausenloy D.J., Riksen N.P. The cardioprotective effects of mineralocorticoid receptor antagonists. Pharmacol. Ther. 2014;142(1):72-87.
  36. Vasan R.S., Evans J.C., Larson M.G., Wilson P.W., Meigs J.B., Rifai N., Benjamin E.J., Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N. Engl. J. Med. 2004;351:33-41.
  37. Vaur L., Danchin N., Genès N., Dubroca I., Etienne S., Ferrières J., Cambou J.P. Epidemiology of myocardial infarction in France: therapeutic and prognostic implications of heart failure during the acute phase. Am. Heart J. 1999;137:4958.
  38. Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E. Jr., Drazner M.H., Fonarow G.C., Geraci S.A., Horwich T., Januzzi J.L., Johnson M.R., Kasper E.K., Levy W.C., Masoudi F.A., McBride P.E., McMurray J.J., Mitchell J.E., Peterson P.N., Riegel В., Sam F., Stevenson L.W., Tang W.H., Tsai E.J., Wilkoff B.L. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2013;62(16):147-239.
  39. Yang J, Young M.J. Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences. Curr. Opin. Pharmacol. 2016;27:78-85.
  40. Zannad F., McMurray J.J., Krum H., van Veldhuisen D.J., Swedberg K., Shi H., Vincent J., Pocock S.J., Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. New Engl. J. Med. 2011 ;364(1 ); 11 -21.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2016

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>